- Home
- ENTA
as 07-26-2024 4:00pm EST
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 303.3M | IPO Year: | 2013 |
| Target Price: | $19.00 | AVG Volume (30 days): | 203.6K |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.08 - $20.04 | Next Earning Date: | 08-05-2024 |
| Revenue: | $72,881,000 | Revenue Growth: | -10.22% |
| Revenue Growth (this year): | -11.01% | Revenue Growth (next year): | 7.14% |
Stock Insider Trading Activity of Enanta Pharmaceuticals Inc. (ENTA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rottinghaus Scott T. | ENTA | Chief Medical Officer | Jul 11 '24 | Sell | $17.08 | 5,375 | $91,805.00 | 21,717 | SEC Form 4 |
| Rottinghaus Scott T. | ENTA | Chief Medical Officer | Jul 11 '24 | Sell | $15.04 | 2,271 | $34,155.84 | 21,717 | SEC Form 4 |
| Rottinghaus Scott T. | ENTA | Chief Medical Officer | Jul 11 '24 | Sell | $15.07 | 4,299 | $64,785.93 | 23,988 | SEC Form 4 |
| Kieffer Tara Lynn | ENTA | Chief Product Strategy Officer | Jun 17 '24 | Sell | $12.33 | 7,266 | $89,589.78 | 32,341 | SEC Form 4 |
| Vance Terry | ENTA | Director | Dec 13 '23 | Sell | $9.12 | 15,295 | $139,490.40 | 5,800 | SEC Form 4 |
| Luu Brendan | ENTA | Sr. VP, Business Dev. | Dec 5 '23 | Sell | $9.63 | 2,125 | $20,463.75 | 36,736 | SEC Form 4 |
| Or Yat Sun | ENTA | Sr. VP, R&D & CSO | Dec 5 '23 | Sell | $9.63 | 2,412 | $23,227.56 | 370,695 | SEC Form 4 |
Latest Enanta Pharmaceuticals Inc. News
ENTA Breaking Stock News: Dive into ENTA Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
Business Wire
2 months ago
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
Simply Wall St.
3 months ago
Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
MT Newswires
3 months ago
JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating
Insider Monkey
3 months ago
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript
Thomson Reuters StreetEvents
3 months ago
Q2 2024 Enanta Pharmaceuticals Inc Earnings Call
Business Wire
3 months ago
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
GuruFocus.com
3 months ago
Enanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...
Compare ENTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENTA Enanta Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.